BioSpace News Archive

Blaine Labs Company is voluntarily recalling one lot of RevitaDerm Wound Care to the consumer level because a bottle of the 1.0 ounce RevitaDerm Wound Care Gel has been found to be contaminated with Bacillus cereus.

n-Lorem a nonprofit Foundation, discovering and providing experimental antisense oligonucleotide medicines to nano-rare disease patients for free, for life, announced Alexion, AstraZeneca’s Rare Disease group, has made a donation of $1 million.

Rising Prevalence Of Chronic Disease, Increasing Awareness Among People Regarding Modern Treatment Methods And Steady Increase In Geriatric Population Are The Prime Reasons Driving The Market – Reports and Data

Growing Awareness Of Cardiac Problems, Technological Advancement In The Procedures, And Accurate Measurements Of Blood Pressure Are Factors Driving Growth In The Global Fractional Reserve Market – Reports and Data.

Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing breakthrough gene therapies and vaccines, announced that it has signed a non-binding letter of intent (LOI) with Liminal BioSciences, Inc.

Enable Injections, Inc. (“Enable”), a company developing and manufacturing the enFuse® platform of investigational wearable drug delivery systems, is pleased to announce $215 million in Series C financing.

Hewlett Packard Enterprise announced new research that demonstrates how supercomputers can be used to test and benchmark computational performance for the quantum computing community, redefining theoretical performance claims that future quantum computers will deliver.

Oxitec Ltd, the leading developer of biological solutions to control pests that transmit disease, destroy crops and harm livestock, announced the publication of early results heralding a new, transformative crop protection solution for the sustainable management of one of the world’s most devastating crop pests.

LUNGevity Foundation, the nation’s leading lung cancer-focused nonprofit organization, is pleased to offer for the second time two lung cancer research award programs to support early-stage lung cancer researchers from underrepresented populations in the biomedical research workforce.

Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative AAV-mediated gene therapies for people with inherited systemic debilitating diseases, today announced that it will deliver a platform presentation and two poster presentations at the 18th Annual WORLDSymposium™.